Similar articles for PMID: 33649135

Year	Number of Results
1986	1
1993	1
1995	4
1996	5
1997	7
1998	3
1999	1
2000	1
2001	3
2002	1
2003	2
2004	2
2005	2
2006	3
2007	5
2008	1
2009	2
2010	2
2011	4
2012	3
2013	3
2014	5
2015	6
2016	8
2017	4
2018	5
2019	3
2020	9
2021	3
2022	1

1

Vaccine Development: Steps to Approval of an Investigational Vaccine.

Walter EB, Moody MA. Walter EB, et al. N C Med J. 2021 Mar-Apr;82(2):141-144. doi: 10.18043/ncm.82.2.141. N C Med J. 2021. PMID: 33649135 Free article. No abstract available.

2

An overview of the regulation of influenza vaccines in the United States.

Weir JP, Gruber MF. Weir JP, et al. Influenza Other Respir Viruses. 2016 Sep;10(5):354-60. doi: 10.1111/irv.12383. Epub 2016 Mar 24. Influenza Other Respir Viruses. 2016. PMID: 27426005 Free PMC article.

3

[From the licensure of vaccines to the recommendation of the Standing Committee on Vaccination in Germany : criteria for the assessment of benefits and risks].

Pfleiderer M, Wichmann O. Pfleiderer M, et al. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Mar;58(3):263-73. doi: 10.1007/s00103-014-2109-y. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015. PMID: 25566841 German.

4

Food and Drug Administration Approval for Use of Hiberix as a 3-Dose Primary Haemophilus influenzae Type b (Hib) Vaccination Series.

Briere EC. Briere EC. MMWR Morb Mortal Wkly Rep. 2016 Apr 29;65(16):418-9. doi: 10.15585/mmwr.mm6516a3. MMWR Morb Mortal Wkly Rep. 2016. PMID: 27124887 Free article.

5

Vaccines under study: non-HIV vaccines.

Conner K, Wuu A, Maldonado V, Bartlett BL, Tyring SK. Conner K, et al. Dermatol Ther. 2009 Mar-Apr;22(2):168-85. doi: 10.1111/j.1529-8019.2009.01229.x. Dermatol Ther. 2009. PMID: 19335728 Review.

6

Vaccine Research--11th Annual Conference: cutaneous formulations, universal vaccinations and recently licensed vaccines.

O'Brien J. O'Brien J. IDrugs. 2008 Jul;11(7):471-4. IDrugs. 2008. PMID: 18600589 No abstract available.

7

Ensuring the optimal safety of licensed vaccines: a perspective of the vaccine research, development, and manufacturing companies.

Kanesa-thasan N, Shaw A, Stoddard JJ, Vernon TM. Kanesa-thasan N, et al. Pediatrics. 2011 May;127 Suppl 1:S16-22. doi: 10.1542/peds.2010-1722D. Epub 2011 Apr 18. Pediatrics. 2011. PMID: 21502248 Review.

8

[Vaccines: from the identification of the microorganism to marketing. How long does it take?].

Terracciano E, Amadori F, Zaratti L, Franco E. Terracciano E, et al. Ig Sanita Pubbl. 2020 Mar-Apr;76(2):143-151. Ig Sanita Pubbl. 2020. PMID: 32877397 Italian.

9

The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon.

Chatterjee A. Chatterjee A. Expert Rev Vaccines. 2014 Nov;13(11):1279-90. doi: 10.1586/14760584.2014.963561. Epub 2014 Sep 26. Expert Rev Vaccines. 2014. PMID: 25256262 Review.

10

Polyvalent vaccines and the national immunisation schedule.

Thompson SC. Thompson SC. Med J Aust. 1996 Sep 16;165(6):346-7. Med J Aust. 1996. PMID: 8862339 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed